What: Boston Magazine discusses how overwhelming Instagram ads for menopause treatments burden women during perimenopause.
Key line: [Details not provided].
Source: Boston Magazine.
The Wall Street Journal examines why women in their 30s and 40s are opting for facelifts earlier than before.
The New York Times’ Wirecutter recommends tools to alleviate menopause symptoms, from cooling sheets to strength training equipment.
Postpartum depression tied to brain changes after childbirth.
KFF explains that Medicaid already has mechanisms in place to prevent fraud and waste, despite recent rhetoric.
NBC News highlights fertility statistics showing a 127% increase in birth rates for women over 40.
Oprah opens up about her menopause journey and brings national attention to a long-ignored health topic.
Mouse trials show that adding rapamycin to surgically removed frozen ovaries increases the number of successful births.
British mother calls for better treatment after her daughter’s suicide due to untreated hyperemesis gravidarum.
NIH announced winners of a competition focused on endometriosis diagnostics using menstrual blood and specialized imaging.
Dan Weldon, nominee for CDC Director, has a long history of restricting abortion access.
FDA ends approval for compound versions of GLP-1 weight loss drugs.
Texas Democrats push for maternal mortality transparency and tracking.
Texas Republicans propose changes to abortion bans after preventable deaths.
Abortion bans reduce OBGYN care access in restrictive states.
Study highlights barriers preventing women from obtaining permanent contraception after delivery.
World Economic Forum explores why improving diagnostics in women’s health is key.
Study shows over 50% of women don’t receive follow-up after cervical dysplasia treatment.
Breast pump startup Willow takes over UK-based Elvie’s assets, signaling tough market conditions for women’s health companies.
Seventeen GOP-led states aim to dismantle privacy protections for abortion patients; judge questions HIPAA’s constitutionality.
XX Factor highlights concerns about cuts to NIH, CDC, and FDA that could impact women’s health research.